Literature DB >> 9353436

Transrectal sonography in staging rectal carcinoma: the role of gray-scale, color-flow, and Doppler imaging analysis.

J P Heneghan1, R R Salem, R C Lange, K J Taylor, L W Hammers.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the efficacy of combining gray-scale sonography with color-flow imaging and pulsed Doppler transrectal sonography in the staging of rectal carcinoma. SUBJECTS AND METHODS: Thirty-nine patients with primary rectal carcinoma underwent transrectal sonography. The rectal masses were staged T1-T2 or T3-T4 on the basis of gray-scale imaging. The local nodes were classified as benign or malignant on the basis of size and echogenicity. In 22 patients, color-flow imaging and pulsed Doppler imaging of the rectal mass and of the local lymph nodes were performed. The peak systolic velocity (PSV) and end diastolic velocity were documented, and the resistive index was calculated.
RESULTS: Gray-scale imaging alone was used to stage T1-T2 masses with 88% sensitivity and 82% specificity. T3-T4 masses were staged with 82% sensitivity and 88% specificity. Overall accuracy was 85%. Gray-scale imaging of lymph nodes using a discriminatory size of less than or equal to 5 mm for benign nodes and greater than 5 mm for malignant nodes yielded a sensitivity of 100%, a specificity of 28%, and an accuracy of 52%. Using receiver operating characteristic curve analysis, we determined that a size of greater than or equal to 7 mm was optimal for characterizing nodes. Such a size provided an accuracy of 83%. PSV of less than 25 cm/sec distinguished T3-T4 from T1-T2 rectal masses with 75% sensitivity, 80% specificity, and 77% accuracy. A PSV of greater than 20 cm/sec classified a node as malignant with 100% sensitivity, 62% specificity, and 76% accuracy. A resistive index of greater than 0.61 classified a node as malignant with 71% sensitivity, 85% specificity, and 80% accuracy.
CONCLUSION: Color-flow imaging and pulsed Doppler imaging are useful additions to gray-scale transrectal sonography in staging primary rectal carcinomas. The combination has most value when evaluating perirectal nodes.

Entities:  

Mesh:

Year:  1997        PMID: 9353436     DOI: 10.2214/ajr.169.5.9353436

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  5 in total

1.  Lymphovascular or perineural invasion may predict lymph node metastasis in patients with T1 and T2 colorectal cancer.

Authors:  Jung Wook Huh; Hyeong Rok Kim; Young Jin Kim
Journal:  J Gastrointest Surg       Date:  2010-04-30       Impact factor: 3.452

2.  Transabdominal Ultrasonography for Preoperative Diagnosis of Lymph Node Metastasis in Colon Cancer: A Retrospective Cohort Study.

Authors:  Ken Imaizumi; Shigenori Homma; Mutsumi Nishida; Takeshi Soyama; Ryosuke Shimura; Yusuke Kudo; Satomi Omotehara; Isao Yokota; Ryo Takagi; Hiroki Matsui; Yoichi Miyaoka; Nobuki Ichikawa; Tadashi Yoshida; Norihiko Takahashi; Akinobu Taketomi
Journal:  Cancer Diagn Progn       Date:  2022-03-03

Review 3.  Practical approach to linear endoscopic ultrasound examination of the rectum and anal canal.

Authors:  Hussein Hassan Okasha; Katarzyna M Pawlak; Amr Abou-Elmagd; Ahmed El-Meligui; Hassan Atalla; Mohamed O Othman; Sameh Abou Elenin; Ahmed Alzamzamy; Reem Ezzat Mahdy
Journal:  Endosc Int Open       Date:  2022-10-17

4.  Analysis of risk factors for lymph nodal involvement in early stages of rectal cancer: when can local excision be considered an appropriate treatment? Systematic review and meta-analysis of the literature.

Authors:  Alessandro Carrara; Daniela Mangiola; Riccardo Pertile; Alberta Ricci; Michele Motter; Gianmarco Ghezzi; Orazio Zappalà; Gianni Ciaghi; Giuseppe Tirone
Journal:  Int J Surg Oncol       Date:  2012-06-19

5.  Biplane transrectal ultrasonography plus ultrasonic elastosonography and contrast-enhanced ultrasonography in T staging of rectal cancer.

Authors:  Yanru Feng; Chanjuan Peng; Yuan Zhu; Luying Liu
Journal:  BMC Cancer       Date:  2020-09-07       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.